Company Profile

HaiHe Biopharma (HK) Limited focuses on discovery, development and commercialization of innovative anti-tumor drugs. Guided by our mission, “Inclusive and open to diversity, innovation oriented to win together and benefit the mankind”, HaiHe Biopharma insists on the way of independent innovation and pursues for global development of Chinese original innovative drugs in partnership with Shanghai Institute of Materia Medica, Chinese Academy of Science (SIMM).

HaiHe consists of three companies: Shanghai HaiHe Pharmaceutical Co., Ltd., Shanghai RMX Biopharma Co., Ltd., and Shanghai HaiShi Biomedical Co., Ltd. (a JV established with China Shijiazhuang Holding Group Co., Ltd. ). The company is led by an academician of the Chinese Academy of Engineering. The senior management team has extensive experiences in drug research and development in China and abroad. HaiHe Biopharma has built a precision medical platform guided by biomarkers, and established a fully integrated pre-clinical evaluation technical platform and clinical study system for innovative drugs, with advanced technology and operation in consistence with international standards and norms, covering subunits from compound synthesis, CMC study, biomarker discovery and validation, medical strategy and clinical study, etc. The company has established a globally competitive innovative drug R&D system and robust product pipeline. There are 11 compounds in clinical and 5 compounds in preclinical studies, among which 9 compounds are discovered in-house.


Address: No. 421 Newton Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai

@2019 Copyright Shanghai HaiHe Pharmaceutical Co.,Ltd All Rights Reserved.

All Rights Reserved. 沪ICP备12016151号

HaiHe Biopharma

on Wechat